Alnylam Pharmaceuticals (ALNY) Stock Buyback History
TTM buyback yield N/A.
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
17.1%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
Diluted vs basic shares (annual)
Weighted average shares from the income statement: diluted (EPS denominator and typical buyback-yield basis) compared with basic.
Shares outstanding (annual)
Year-over-year change in diluted weighted average shares (industry-standard for EPS and per-share capital return). Green is fewer shares vs the prior fiscal year; red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield
Buybacks vs stock-based compensation
TTM coverage: 0.00x (buybacks ÷ SBC). Bars are fiscal-year totals.
Buyback spending history
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $348.24M | −$348.24M | 0.13B | 5.5% | — |
| 2024 | $0.00 | $272.08M | −$272.08M | 0.13B | 2.2% | — |
| 2023 | $0.00 | $221.68M | −$221.68M | 0.12B | 2.6% | — |
| 2022 | $0.00 | $230.65M | −$230.65M | 0.12B | 2.7% | — |
| 2021 | $0.00 | $165.72M | −$165.72M | 0.12B | 3.0% | — |
| 2020 | $0.00 | $139.87M | −$139.87M | 0.11B | 5.2% | — |
| 2019 | $0.00 | $174.84M | −$174.84M | 0.11B | 8.6% | — |
| 2018 | $3.47M | $157.75M | −$154.28M | 0.10B | 11.1% | 0.05% |
| 2017 | $257.00K | $92.82M | −$92.56M | 0.09B | 5.8% | 0.00% |
| 2016 | $596.00K | $75.53M | −$74.93M | 0.09B | 1.9% | 0.02% |
| 2015 | $378.00K | $45.78M | −$45.41M | 0.08B | 13.1% | 0.00% |
| 2014 | $15.99M | $33.06M | −$17.07M | 0.07B | 20.7% | 0.21% |
| 2013 | $1.39M | $20.70M | −$19.31M | 0.06B | 22.4% | 0.03% |
| 2012 | $359.00K | $12.36M | −$12.00M | 0.05B | 18.6% | 0.04% |
| 2011 | $0.00 | $16.80M | −$16.80M | 0.04B | 0.9% | — |
| 2010 | $0.00 | $19.34M | −$19.34M | 0.04B | 1.0% | — |
| 2009 | $0.00 | $20.17M | −$20.17M | 0.04B | 1.4% | — |
| 2008 | $0.00 | $18.03M | −$18.03M | 0.04B | 6.3% | — |
| 2007 | $0.00 | $14.47M | −$14.47M | 0.04B | 21.2% | — |
| 2006 | $0.00 | $8.30M | −$8.30M | 0.03B | 45.3% | — |
| 2005 | $0.00 | $0.00 | $0.00 | 0.02B | 84.7% | — |
| 2004 | $0.00 | $4.11M | −$4.11M | 0.01B | 1160.9% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 0.00B | 184.5% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 0.00B | — | — |
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
TTM buybacks vs headroom (FCF − dividends, TTM)0% of headroom
Headroom $465.38M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Does Alnylam Pharmaceuticals buy back its own stock?
- Yes, Alnylam Pharmaceuticals (ALNY) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Alnylam Pharmaceuticals diluting shareholders?
- Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Alnylam Pharmaceuticals's share count changed?
- Diluted weighted average shares changed by about 17.1% over roughly five fiscal years (annual income statement data).